Core Viewpoint - The company plans to issue shares to acquire 100% equity of Shandong Weigao Puri Pharmaceutical Packaging Co., Ltd. from related parties, which constitutes a significant asset restructuring under regulatory guidelines [1] Group 1: Transaction Details - The transaction involves the acquisition of equity from Shandong Weigao Group Medical Polymer Co., Ltd., Weihe Shengxi Enterprise Management Consulting Center (Limited Partnership), and Weihe Ruiming Enterprise Management Consulting Partnership (Limited Partnership) [1] - This transaction is classified as a related party transaction and is subject to various approvals, including the board of directors, shareholders' meeting, Shanghai Stock Exchange, and China Securities Regulatory Commission [1] Group 2: Financial Status - As of the date of the announcement, the audit and evaluation of the target assets have not been completed, and the relevant financial data and transaction price are yet to be determined [1]
威高血净：拟购买山东威高普瑞医药包装有限公司100%股权